Poland IVF Service Market Analysis Sample Report 2022 to 2030

Poland In Vitro
Fertilization (IVF)
Service Market
Analysis
A sample report on
Includes Market Size, Market Segmented
by Types and Key Competitors (Data
forecasts from 2023 – 2030F)
www.insights10.co
m

This report presents a strategic analysis of the Poland In Vitro
Fertilisation (IVF) Service Market Analysis and a forecast for its
development in the medium and long term. It provides a comprehensive
overview of the market value, dynamics, segmentation, main players,
growth and demand drivers, challenges & future outlook, etc. This is one of
the most comprehensive reports about the Poland In Vitro Fertilisation
(IVF) Service Market Analysis, and offers unmatched value, accuracy,
and expert insights.

3
A Sample Report on Poland In Vitro Fertilisation (IVF) Service Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
▪ Sector-focused financial engineers who
carry interdisciplinary backgrounds across
asset classes
▪ Guided by specific value chain frameworks
in sectors with strong macro tailwinds,
Recharge Capital invests with agile
vehicles to best capture the opportunities in
the targeted themes
▪ It has themes of synthetic biology,
semiconductor enablements, digital assets,
women’s healthcare and fintech
infrastructure
▪ Assessing the current size and growth
potential of the Poland In Vitro Fertilisation
(IVF) Service Market
▪ Identifying the key trends in the Poland In
Vitro Fertilisation (IVF) Service Market
▪ Analyzing the competitive landscape of the
Poland In Vitro Fertilisation (IVF) Service
Market
▪ Providing insights into the regulatory
landscape of the Poland In Vitro
Fertilisation (IVF) Service Market
▪ Increase of Infertility among couples in
Poland, increase in mean age of child
bearing women in Poland
▪ This is driving the demand for In Vitro
Fertilisation (IVF) ServiceMarket in Poland
▪ Technological developments of in vitro
fertilization and rising medical tourism in
Poland due to low living cost also acts as
market growth driver
Our Understandings
Recharge Capital
Summary
Report Objective Key Insight

5
Table of Content
CONTENT PG. NO.
1. Poland In Vitro Fertilisation (IVF) Service Market Overview 7-19
1.1. Overview
1.2. Poland Overview
1.3. Economic Overview: Poland
1.4. Poland In Vitro Fertilisation (IVF) Service Market
1.5. Healthcare Services in Poland
1.6. Healthcare Scenario in Poland
1.7. Health Insurance Coverage: Poland
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting 20-27
2.1 Market size and forecasts (Excel and Methodology)

6
Table of Content
CONTENT PG. NO.
2.2. Market Segmentation
3. Market Dynamics 28-32
3.1. Market Growth Drivers
3.2. Market Restraints
4. Competitive Landscape 33-43
4.1. Major Market Share
4.2. Key Company Profile
5. Reimbursement Scenario 44-49
5.1. Reimbursement Regulation
5.2. Reimbursement Process for In Vitro Fertilisation (IVF) Service
6. Methodology & Scope 50-77

Poland In Vitro Fertilisation (IVF) Service Market Analysis
1. In Vitro Fertilisation (IVF) Service Market Overview

8
1.1 Statistics at a Glance: In Vitro Fertilisation (IVF) Service Market in the World
Prevalence of In Vitro Fertilisation (IVF) Service Market
▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an understanding
of the topic, which includes the prevalence
of the disease, the application of medical
devices, new technology, and other details
related to the topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
$ 696 Mn
Global in vitro fertilization
service market size in 2022
8%-10%
Couples globally suffer from
infertility which is around 80
million couples worldwide
according to WHO
10-15%
Couples globally suffer from
secondary infertility that is
inability to have second
offspring
8.9%
CAGR at which global in vitro
fertilization service market
size is expected to grow from
2022-2030
17.5%
Lifetime prevalence of
infertility in low and middle
income countries
16.5%
Lifetime prevalence of
infertility in low and middle
income countries

9
1.1 Statistics at a Glance:In Vitro Fertilisation (IVF) Service Market in the World
North America
~ Market Size of
$8.9 Bn
Europe
~Revenue to reach
$6.29 Bn by 2030
Asia
-Fastest CAGR
Africa
~Market Size of
$0.26 Bn
Poland Market
~$103 Mn
Illustrative

10
1.2 Poland Overview
38.5 Mn
Is the population of
Poland, in 2022
41.3
Is the median age
in Poland , in 2022
$688 Bn
Is the Gross
Domestic Product
(GDP) in Poland in
2022
$3.34 k
per capita was the
amount of national
health expenditures in
2022
report
▪ In this section you will get an
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest

11
1.3 Economic Overview: Poland
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Poland , (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Poland , (2020-2030)
Population Split (2023)
55-
64
0-
14
15-
24
25-
54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

12
report
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic in Poland
interest
15-20%
Polish couples suffer
from infertility
36
Years is average age of
women seeking for
fertility treatment
35.2%
Success rate of in-vitro
fertilization procedures in
Poland
$103 Mn
Market size of IVF
services in Poland
$3696
Price of IVF treatment
using own eggs in
Poland
3.4%
Population is suffering
from infertility in Poland
1.4 Poland In Vitro Fertilisation (IVF) Service Market
Prevalence of IVF Services

13
1.5 Healthcare Services in Poland
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Poland Healthcare Services Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Healthcare Services market in Poland , which includes the market size, current
trends and other details related to the topic
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
subject matter of interest
Illustrative

14
1.6 Healthcare Scenario in Poland
▪ Primary and Specialist Care: The healthcare system in Poland includes primary care facilities such as clinics and general
practitioners, as well as specialized healthcare services provided by specialists in hospitals and outpatient clinics. Patients generally
need a referral from a primary care physician to access specialist care
▪ Infrastructure and Facilities: Poland has a well-developed healthcare infrastructure with a network of hospitals, clinics, and
healthcare facilities across the country. Major cities have modern hospitals equipped with advanced medical technologies, while
rural areas may have limited healthcare resources and face challenges in terms of accessibility
▪ Waiting Times: Waiting times for certain medical procedures and specialist appointments can be a challenge in the Polish
healthcare system. This can result from a shortage of specialists, high patient demand, and resource constraints. Efforts are being
made to reduce waiting times and improve access to healthcare services
▪ Public and Private Healthcare: In addition to the public healthcare system, Poland also has a private healthcare sector. Private
healthcare providers offer services that are not covered by the public system, and individuals can choose to access private
healthcare services by paying out-of-pocket or purchasing private health insurance
▪ Healthcare Funding: The Polish healthcare system is funded through a combination of public funds, including contributions from
employees and employers, as well as government allocations from the state budget. The National Health Fund plays a key role in
managing and allocating healthcare funds
▪ Digitalization and E-health: Poland is embracing digitalization in healthcare with the implementation of e-health solutions.
Electronic medical records, telemedicine, and online appointment booking systems are being introduced to improve healthcare
efficiency, accessibility, and patient outcomes
▪ Pharmaceutical Industry: Poland has a well-established pharmaceutical industry and is a major market for pharmaceutical
products. The country also produces some generic drugs, which contribute to cost savings in healthcare

15
1.6 Healthcare Scenario: Patient Journey
Presentation Diagnosis Treatment Follow up
A suspected diagnosis is
usually made, based on
physical examination and
detailed patient and family
history
Prenatal screening/
Neonatal screening
Initial Diagnosis
Complete blood count
(evaluate number &
quality of RBCs, Hb &
WBCs)
Imaging (confirm bone
related changes or
respiratory problems)
Bacterial cultures of
blood, sputum, urine,
stool (detect any
infection)
Genetic testing (detect
the type of SCD)
Confirmatory Diagnosis
Prevention and management of
crisis:
• For VOC and Splenic
Sequestration: HU, Endari,
Adakveo, Oxbryta
• For infections: Antibiotics,
Vaccines
Prevention and management of
complications:
• Stroke: Chronic transfusions, HU
• Long term follow-up is required for
patients with SCD
• Annual assessment: CBC and
reticulocyte count, iron status, liver
and renal function tests, urinalysis,
LDH, vitamin D level and
neurocognitive assessment
• ESOD (End Stage Organ Damage)
evaluation starting from age 7
• Yearly Transcranial Doppler test to
determine risk of stroke
Stakeholders
PCP, paediatrician,
neonatologist,
haematologist and genetic
counsellor
PCP, pediatrician, medical geneticist,
hematologist, gynecologist and pathologist
PCP, pediatrician, medical geneticist,
cardiologist, hematologist,
endocrinologist, psychologist and
psychiatrist
PCP, pediatrician, neonatologist,
endocrinologist, cardiologist,
hematologist, orthopedist, psychologist
and psychiatrist
Depending on the organ complications,
the treatment involves different
specialists at different times
Illustrative

16
1.7 Health Insurance Coverage: Poland
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Public
Private
Any other public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire
calendar year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed by Private insurance (18.9%), Public insurance (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and
CHAMPVA health care (1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
Public 58,541 60,226 0.5
Private 58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
Illustrative

17
1.8 Budget of Poland Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Public $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Private $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Public
3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Private
2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Public spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Private spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

18
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

19
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Oracle acquisition of
Cerner
Acquisition $28.3 Bn June, 2022
▪ Oracle’s acquisition of Cerner is big tech’s latest foray into the
healthcare system, promising better outcomes
▪ Oracle acquire Cerner through an all-cash tender offer for $95.00
per share, or approximately $28.3 Bn in equity value
▪ Cerner is a leading provider of digital information systems used
within hospitals and health systems to enable medical
professionals to deliver better healthcare to individual patients
and communities
GSK acquisition of
Acquisition $2 Bn April 2023
▪ GSK has acquire BELLUS for US$14.75 per share of common
stock in cash representing an approximate total equity value of
US$2.0 billion
▪ BELLUS is a late-stage biopharmaceutical company working to
better the lives of patients suffering from persistent cough
▪ Acquisition further strengthens specialty medicines and
respiratory pipeline with camlipixant, a highly selective P2X3
antagonist and potential best-in-class treatment for refractory
Latest Deals In Poland
Illustrative

2. Market Size and Forecasting

21
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Poland In Vitro Fertilisation (IVF) Service Market Forecast, 2022-2030
(in $Bn)
report
understanding of the overall In Vitro
Fertilisation (IVF) ServiceMarket in Poland,
which includes the market size, current
trends and other details related to the topic
interest
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Poland Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Poland Market Size (Bn $) 61 74 84 87 91 95 99 106
Illustrative

22
2.2 Snapshot of Poland In Vitro Fertilisation (IVF) Service Market Segmentation
▪ In this section you will get an understanding of the segmentations which will cover the Poland IVF Service Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
By Product
Equipment
Reagents & Media
Accessories
By Cycle
Fresh Non-donor IVF
Cycles
Frozen Non-donor IVF
Cycles
Frozen Donor IVF
Cycles
Fresh Donor IVF
Cycle
By Type
Conventional IVF
IVF with ICSI
IVF with Donor Eggs
Others
End-User
Fertility Clinics
Hospitals & Surgical
Centers
Cryobanks

23
Poland IVF Service Market Share, By Product (2022)
Equipment
Reagents &
Media
Accessories
2.2.1 Market Segmentation: By Product
▪ Equipment:
o Sperm Analyzer Systems
o Imaging Systems
o Ovum Aspiration Pumps
o Micromanipulator Systems
o Incubators
o Gas Analysers
o Laser Systems
o Cryosystems
o Sperm Separation Devices
o IVF Cabinets
o Anti-vibration Tables
o Witness Systems
▪ Reagents & Media
o Cryopreservation Media
o Embryo Culture Media
o Ovum Processing Media
o Sperm Processing Media
▪ Accessories

24
Poland IVF Service Market Share, By Cycle Type (2022)
Fresh Non-donor
IVF Cycles
Frozen Non-
donor IVF Cycles
Frozen Donor IVF
Cycles
Fresh Donor IVF
Cycle
report
interest
2.2.2 Market Segmentation: By Cycle

25
Poland IVF Service Market Share, By Type (2022)
Conventional IVF
IVF with ICSI
IVF with Donor
Eggs
2.2.3 Market Segmentation: By Type
report
interest

26
Poland IVF Service Market Share, By End-User (2022)
Fertility Clinics
Hospitals &
Surgical Centers
Cryobanks
2.2.4 Market Segmentation: By End-User
report
interest

3. Market Dynamics

28
3.1 Market growth drivers
▪ Increase in age of women decreases the fertility of women and this acts
as a market growth driver for in vitro fertilization in Poland
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
2010 2022 2030
Increasing Age of Women at Child Birth
3.1.1 Increasing age of women at child birth, In 2022, the average age was 30.2 years. This is an increase from the
average age of 29.7 years in 2020
Illustrative

29
3.1 Market growth drivers (continued)
Top countries that are leveraging
technology for R&D in IVF services
United States
Japan
Germany
South Korea
China
United Kingdom
France
Canada
Australia
Israel
Switzerland
Singapore
Sweden
Netherlands
Italy
Spain
Belgium
Denmark
Austria
Norway
3.1.2 Technological Advancement like Cryopreservation, ICSI, PICSI, PGD, PGS. In 2022, the government allocated
about $2.3 Mn for research and development in IVF Services and Private companies allocated about $1.1 Mn
▪ Poland is highly technologically equipped when it comes to IVF
technology and various research and development activities are
going on for the same which acts as a market growth driver
▪ Please be aware that this sample report is intended to provide you
with a brief overview of the kind of information and analysis that will
be presented in the final report
▪ Final report will be comprehensive and detailed, and it will include
data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

30
3.1 Market growth drivers (continued)
3.1.3 Increasing medical tourism in Poland. In 2022, Poland is estimated to have welcomed over 442,900 medical
tourists. This is a significant increase from the 378,000 medical tourists who visited Poland in 2020.
▪ Medical tourism in Poland is increasing at a high rate due to low
cost of living in Poland as compared to rest countries in Europe
and latest medical technologies in Europe
▪ Please be aware that this sample report is intended to provide
you with a brief overview of the kind of information and analysis
that will be presented in the final report
▪ Final report will be comprehensive and detailed, and it will include
data, analysis, trends, and other relevant information related to
the topic or subject matter of interest
2010 2022 2030
Medical Tourism in Poland
Illustrative

31
3.2 Market restraints
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
3.2.1 3.2.1 In 2022, the average
cost of a IVF was around €3,000,
which depends on the clinic and
specific treatment
▪ IVF procedure is expensive and
this acts as a market growth
restraint for IVF Service market
in Poland
▪ In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
▪ Final report will be
comprehensive and detailed, and
it will include data, analysis,
trends, and other relevant
information related to the topic or
3.2.3 Lack of insurance coverage
in Poland because there is no
universal health insurance
coverage
▪ Insurance and reimbursement
challenge also acts as a market
growth restraint
3.2.2 Success rate for IVF service
is 30% in Poland, which varies
depending on different factors
▪ Due to less success rate of IVF
procedure patients are hesitant
to go for the procedure
Illustrative

4. Competitive Landscape

33
4.1 Major Market Share
XX
Other
▪ Poland IVF Service Market is a highly
competitive space, with many companies
developing and marketing cancer
treatments
▪ Some of the top companies in Poland IVF
Service Market based on revenue and
market share include
interest
Revenue of Major players in Poland IVF Service Market
($ Mn)
Illustrative

34
4.2 Key Company Profile
1 InviMed
3 CCRM Fertility
5 Create Health
7 Aevitas Fertility Clinic
9 Prelude Fertility
2 Bloom IVF
4 Oxford Fertility
6 Medicover
8 BioART Fertility Clinic
Genesis
10
▪ Here is the list of top 10 companies which will
cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and Collaboration
o Financials
▪ If there are specific companies that you would
like to be included in the report, please let us
know via email
Key Note:
Illustrative

35
4.2.1 InviMed
Founded in: 1995
HQ: Warsaw, Poland
Type: Private
Revenue: -
Website: www.invimed.pl
▪ InviMed offers a full range of IVF services, including egg donation,
embryo donation, and gestational surrogacy
▪ InviMed's success rate for IVF is over 54%. This is higher than
the average success rate for IVF in Poland, which is around 35%
▪ Polish Ministry of Health and the European Society of Human
Reproduction and Embryology has accredited InviMed which
indicates the clinic's high standards of quality and safety
Solutions offered by InviMed
⮚ In Vitro Fertilization
⮚ Egg Donation
⮚ Embryo Donation
⮚ Gestational Surrogacy
⮚ Cryopreservation
Support Services Location
Counselling Warsaw
Support Group Krakow
Financial Assistance Poznan
InviMed Recent Activity / Press Coverage
InviMed was featured in an article in the Polish newspaper Rzeczpospolita
in April 2023. The article praised InviMed for its high success rate and its
wide range of IVF services
InviMed was also featured in an article in the British newspaper The
Telegraph in May 2023
InviMed has recently opened a new clinic in Gdynia, Poland. This brings the
total number of InviMed clinics to four
Illustrative

36
4.2.1 InviMed (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
One of the largest pharmaceutical
distributors in the United States, McKesson
has been a long-standing distribution
partner for Roche
Cardinal Health is a Fortune 500 healthcare
services company that provides
pharmaceutical distribution services to
Roche
It is one of the largest drugstore chains in
the United States and Europe, and its
extensive network of retail locations and
distribution centers make it an important
distribution partner for Roche
A leading healthcare services provider in
Asia, Zuellig Pharma is a distribution
partner for Roche in several Asian countries
One of the largest pharmaceutical
wholesalers in Europe, PHOENIX Group
distributes Roche's products in several
European countries
Roche has been working with SAP, a
leading software company, to develop
digital solutions for its healthcare products
A leading Swiss biotechnology company,
Lonza provides Roche with contract
manufacturing services for the production of
its biologics and pharmaceuticals
Roche has a strategic partnership with
Microsoft to leverage its cloud computing
and AI technologies in the development of
new healthcare products
Thermo Fisher Scientific is a leading
provider of analytical instruments, reagents,
and laboratory services
GE Healthcare provides Roche with
advanced medical imaging and diagnostics
technologies, including CT scanners and
MRI machines
Illustrative

37
Company Name Type
Amount /
Duration
Year Key Pointers
Roche
Partnership $500 Mn
December,
2022
▪ InviMed and Roche announced a global collaboration to develop
and commercialize a new blood test for early detection of cancer
▪ Partnership includes an upfront payment of $500 Mn to InviMed,
as well as potential milestone payments of up to $1 Bn
▪ InviMed and Roche’s partnersship is a major step forward in the
development and commercialization of the new blood test
▪ Test has the potential to revolutionize the way cancer is detected
and treated
Guardant Health
Partnership $100 Mn
September,
2022
▪ InviMed partnered with Guardant Health to develop and
commercialize a new blood test for early detection of multiple
myeloma
▪ Test developed is called the InviMed MyelomaSEEK which is a
multi-analyte blood
▪ Partnership between InviMed and Guardant Health is a significant
development in the fight against multiple myeloma
▪ Two companies have a strong track record of developing and
Latest Deals - Mergers and Acquisitions
Illustrative

38
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030 ▪ Please be aware that this sample report is
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

39
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for Cancer Recent Activity / Press Coverage
Illustrative

40
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

41
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

42
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Reimbursement Scenario

44
5.1 Reimbursement Regulation
The reimbursement scenario in the US cancer market is complex and can vary
depending on the specific treatment, setting of care, and insurance coverage.
Here are some key points to consider:
▪ Public Insurance:
o Public insurance is a federal health insurance program for people aged
65 and older, as well as people with certain disabilities or health
conditions
o Public insurance covers many cancer treatments, including
chemotherapy, radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
▪ Private Insurance:
o Private insurance is a joint federal-state program that provides health
insurance for people with low incomes
o Private insurance coverage for cancer treatments can vary by state, and
may be subject to limits on the amount and type of treatment covered
o Private insurance coverage for cancer treatments can also vary widely
depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Public insurance and Private insurance
together provide health insurance
coverage for more than 4 in 10 Polandns
Public
17%
Private
21%
Employer-Sponsored
49%
Other…
Other Public
1%
Uninsured
9%
Health Insurance Coverage, 2022
Illustrative

45
5.1 Reimbursement Regulation (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover
certain preventive services, including cancer screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as cancer
▪ Reimbursement for New Treatments:
o Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs
often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest Illustrative

46
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
◼ Public healthcare coverage is provided by the government and includes programs like
Public insurance and Private insurance
◼ Public insurance is a federal program that provides healthcare coverage to individuals
who are 65 years of age or older, as well as certain younger people with disabilities
◼ Private insurance is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

47
5.2 Reimbursement Process for In Vitro Fertilisation (IVF) ServiceDiagnosis
The reimbursement process in the Poland healthcare system can be complex and can vary depending on the type of healthcare
service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

48
5.3 Reimbursement Process for In Vitro Fertilisation (IVF) ServiceTreatment
The reimbursement process in the Poland healthcare system can be
complex and can vary depending on the type of healthcare service, the
healthcare provider, and the insurance coverage. Here are the general
steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
FDA
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
Illustrative

6. Methodology & Scope

Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify
the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
that is currently not a part of our scope as a
part of customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

Insights10 is a healthcare focused market research
firm founded with an aim of being an insights driven
company in the data driven world and delivering
actionable insights that can drive decision and
strategy making process for businesses
www.insights10.com
Lifesciences Market
Research Reports you
can trust

www.insights10.com
A large database of over 30,000 syndicated market
research reports in Pharmaceutical and healthcare
sector at global, regional as well as country level. We
also provide customized research reports tailor made
to suit your needs
Get actionable insights to
take informed business
decisions

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com

Whether you are looking to expand into new areas,
develop new products, or take advantage of new
opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Pharmaceutical
(Diseases & Drugs)
Digital
Health
Medical
Devices
across various categories
Market Research Reports

FEATURED REPORTS FREE SAMPLE
REPORTS
TRENDING TOPICS

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes us different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Share Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7
Table of Contents

Subscription
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service
Primary
Research
Customized
Reports
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with
the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working
with some of the best organizations in the world,
generating insights that provides substantial competitive
advantage.”
Dr. Purav Gandhi
Founder & CEO

Purav is a physician and an entrepreneur
with 12+ years of experience in Healthcare
& Life Sciences industry spanning across
strategy, market access, health informatics
and RWE, digital health, analytics and data
science. Purav studied medicine from
Gujarat University and also completed his
MBA from IIM-Kozhikode. Purav started
his career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of experience
in management consulting in the
Life Sciences sector, and has
worked with diverse multinational
firms in the US, India, Middle East
and APAC regions. His primary
area of interest is Customer and
Market Strategy, Market Access,
and Digital Health with special
focus on emerging markets like
Africa, Middle East and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research & marketing
professional with a progressive
experience of over 20 years in Life
Sciences, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across diff.
markets (America, Europe, Africa, APAC
and Middle East). Her areas of expertise
include: Indentifying emerging trends in life
sciences industry, Competitor landscape
assessment, Disease opportunity
assessments etc. She is a pro in secondary
and primary research with a deep domain
expertise in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

www.insights10.com
Thank you
We truly appreciate your business and
look forward to serving you.

Poland IVF Service Market Analysis Sample Report 2022 to 2030

Recommended

Recommended

More Related Content

Similar to Poland IVF Service Market Analysis Sample Report 2022 to 2030

Similar to Poland IVF Service Market Analysis Sample Report 2022 to 2030 (20)

More from Insights10

More from Insights10 (8)

Recently uploaded

Recently uploaded (20)

Poland IVF Service Market Analysis Sample Report 2022 to 2030